Introduction {#acn351070-sec-0005}
============

Multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD) are chronic inflammatory demyelinating diseases of the central nervous system.[^1^](#acn351070-bib-0001){ref-type="ref"} These disorders are characterized by relapses and deterioration, which necessitates biomarkers for long‐term disease monitoring.[^2^](#acn351070-bib-0002){ref-type="ref"} With the recent development of ultrasensitive single‐molecule array (Simoa) technology,[^3^](#acn351070-bib-0003){ref-type="ref"} serum neurofilament light protein (NfL), a neuronal damage marker, and glial fibrillary acidic protein (GFAP), an astrocyte‐damage marker, have been suggested as a good biomarker candidate with high sensitivity.[^4^](#acn351070-bib-0004){ref-type="ref"}, [^5^](#acn351070-bib-0005){ref-type="ref"}, [^6^](#acn351070-bib-0006){ref-type="ref"}, [^7^](#acn351070-bib-0007){ref-type="ref"}, [^8^](#acn351070-bib-0008){ref-type="ref"}, [^9^](#acn351070-bib-0009){ref-type="ref"}, [^10^](#acn351070-bib-0010){ref-type="ref"} However, processes associated with aging, such as neurodegeneration and related astrogliosis may influence these protein biomarkers;[^6^](#acn351070-bib-0006){ref-type="ref"}, [^11^](#acn351070-bib-0011){ref-type="ref"}, [^12^](#acn351070-bib-0012){ref-type="ref"}, [^13^](#acn351070-bib-0013){ref-type="ref"}, [^14^](#acn351070-bib-0014){ref-type="ref"} thus, these proteins' clinical implications may differ depending on patient age.

The pathogenic mechanisms and disease courses of MS and NMOSD are different.[^1^](#acn351070-bib-0001){ref-type="ref"} MS affects myelin and oligodendrocytes, the pathogenic antigen of which remains elusive, whereas NMOSD is an astrocytopathy that targets aquaporin‐4 (AQP4) protein in astrocytes.[^1^](#acn351070-bib-0001){ref-type="ref"} MS progression is largely independent of inflammatory relapsing activity; neurodegenerative processes that are separate from clinical relapsing events may be important in this disorder. Conversely, a progressive phase is rare in NMOSD and neurodegeneration in this disorder depends mainly on inflammatory relapses.[^1^](#acn351070-bib-0001){ref-type="ref"}

We hypothesized that the clinical implications of serum protein markers associated with disease activity may change with age and their changing patterns may differ between MS and NMOSD. To this end, we investigated the serum levels of NfL and GFAP in consecutive patients with MS and NMOSD. We evaluated correlations between the levels of these biomarkers and disease severity in patients with MS and NMOSD and compared the degrees of correlation according to age within and between disease groups.

Methods {#acn351070-sec-0006}
=======

Patients {#acn351070-sec-0007}
--------

Consecutive patients with MS and NMOSD[^15^](#acn351070-bib-0015){ref-type="ref"} who visited the Department of Neurology at the Asan Medical Center (Seoul, Korea) were prospectively recruited between July 2018 and February 2019. Enrolled MS and NMOSD patients fulfilled the 2017 McDonald criteria[^16^](#acn351070-bib-0016){ref-type="ref"}, [^17^](#acn351070-bib-0017){ref-type="ref"} and the 2015 Wingerchuk criteria,[^15^](#acn351070-bib-0015){ref-type="ref"} respectively. All these patients underwent tests for antibodies against AQP4 protein and myelin oligodendrocyte glycoprotein (MOG) by a cell‐based assay. For the NMOSD group, we only included patients seropositive for anti‐AQP4 antibody; the absence of history of optic neuritis was not an exclusion criterion. We did not include patients who revealed anti‐MOG antibodies to promote our research purposes. The Expanded Disability Status Scale (EDSS) score was evaluated at the time of blood sampling. Our Institutional Review Board approved this study (No. 2018‐0653), and written informed consent was obtained from all participants.

Serum sampling and analysis {#acn351070-sec-0008}
---------------------------

All participants underwent Simoa analysis. Serum samples were collected and stored at −80℃ according to standardized procedures.[^18^](#acn351070-bib-0018){ref-type="ref"} Samples were thawed immediately before analysis. NfL and GFAP levels were measured in duplicate using a Simoa HD‐1 Analyzer (Quanterix, MA, USA) at PrismCDX (Gyeonggi‐do, Korea), by an investigator who was blinded to the clinical information.[^19^](#acn351070-bib-0019){ref-type="ref"}, [^20^](#acn351070-bib-0020){ref-type="ref"} Serum samples were diluted to 1:4 according to the Quanterix guideline and other study groups,[^6^](#acn351070-bib-0006){ref-type="ref"}, [^7^](#acn351070-bib-0007){ref-type="ref"}, [^8^](#acn351070-bib-0008){ref-type="ref"}, [^9^](#acn351070-bib-0009){ref-type="ref"}, [^21^](#acn351070-bib-0021){ref-type="ref"} while the quantification limit was 0.104 pg/mL for NfL, and 0.221 pg/mL for GFAP; all results were above the quantification limit. The mean intra‐assay coefficients of variation for the NfL and GFAP levels were 4.2% and 2.9%, respectively. All intra‐assay duplicate coefficients of variation for the samples were less than 20%.

Statistical analysis {#acn351070-sec-0009}
--------------------

The chi‐squared or Mann--Whitney *U* test was performed to compare variables between MS and NMOSD patients; serum marker levels were log transformed to meet the normal assumption. An analysis of covariance was conducted to compare serum markers, adjusting for important clinical variables (age, EDSS score, days from the last attack to blood sampling, recent relapses \<60 days) that may affect the serum marker levels. Pearson correlation coefficients were calculated to evaluate correlations among the log‐transformed levels of serum biomarkers within each disease group. Then, associations between these serum markers and clinical variables (age, disease duration, and EDSS score) were also calculated with Pearson correlation coefficients; age was used as a continuous variable in these analyses. Linear regression models were also applied to identify associations between EDSS scores and serum marker levels. In these models, regression coefficients (β) were back‐transformed to the original scale to reflect multiplicative effects.[^6^](#acn351070-bib-0006){ref-type="ref"}, [^7^](#acn351070-bib-0007){ref-type="ref"}

To assess whether the clinical significance of serum markers would differ depending on patient age, we evaluated the degrees of association between the biomarkers and EDSS scores in three ways, according to the age groups. First, we analyzed the association by stratification of decade‐year groups (≤30, 31--40, 41--50, 51--60, ≥61 years). Next, to increase the number of patients in each group, we performed the analysis after classifying the patients into three age groups (≤44, 45--54, and ≥55 years) based on previous studies.[^22^](#acn351070-bib-0022){ref-type="ref"}, [^23^](#acn351070-bib-0023){ref-type="ref"}, [^24^](#acn351070-bib-0024){ref-type="ref"} Finally, we set up two age groups according to the median age to verify the results from the analysis of the three age groups. The degrees of correlation between the disease (or age) groups were compared using Fisher's z‐transformation of correlation coefficients. We evaluated correlations between the disease (MS vs. NMOSD) groups and between the age (≤44 vs. 45‐54 vs. ≥55 years) groups. When correlations between the age groups were compared, the youngest group was referenced; a Bonferroni correction was performed to correct for multiple comparisons.

The period from the last clinical attacks to blood sampling was shorter in the NMOSD group than the MS group. Hence, we proceeded to age‐group analyses using only data from patients who had their last clinical attack within the previous 5 years to balance the variable. Significance was set at two‐tailed *P* \< 0.05. All analyses were conducted using Stata version 13.0 (StataCorp., TX, USA).

Data availability {#acn351070-sec-0010}
-----------------

The authors are willing to provide the anonymized data related to this work upon reasonable request.

Results {#acn351070-sec-0011}
=======

During the study period, 119 patients met the McDonald criteria, while 63 patients fulfilled the Wingerchuk criteria with anti‐AQP4 antibodies. Of them, two patients in the former group had anti‐MOG antibodies, thus were not included in this analysis. A total of 180 patients (117 MS and 63 NMOSD) were finally enrolled (Table [1](#acn351070-tbl-0001){ref-type="table"}). The median age was 47 years and 142 (78.9%) patients were female. NMOSD patients were older than MS patients at the time of sampling and had more frequent relapses and recent attacks and a higher EDSS score. The period between the last clinical attack and blood sampling was shorter in the NMOSD group. NfL was quantified in 174 and GFAP in 168 patients. Serum NfL and GFAP levels were higher in NMOSD patients than MS patients; after adjusting for important clinical variables that may affect biomarker levels (age, EDSS score, days from the last attack to blood sampling, recent relapse \<60 days), only GFAP levels remained significantly elevated in NMOSD patients.

###### 

Baseline characteristics between patients with multiple sclerosis and those with seropositive (anti‐aquaporin‐4 antibody) neuromyelitis optica spectrum disorders.

+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
|                                                               | MS                   | NMOSD                 | *P*     | *P* [†](#acn351070-note-0003){ref-type="fn"} |
+===============================================================+======================+=======================+=========+==============================================+
| Age at present                                                | 45 \[34--54\]        | 54 \[46--60\]         | \<0.001 |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
| Age at onset                                                  | 33 \[25--42\]        | 44 \[35--52\]         | \<0.001 |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
| Follow‐up, years                                              | 10 \[5--13\]         | 8 \[3--14\]           | 0.077   |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
| Days from the last attack                                     | 1068 \[387--2883\]   | 633 \[127--1311\]     | 0.002   |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
| Female                                                        | 85 (72.6)            | 57 (90.5)             | 0.005   |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
| No. of attacks                                                | 3 \[1--4\]           | 3 \[2--5\]            | 0.265   |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
| No. of ON attacks                                             | 0 \[0--1\]           | 1 \[0--2\]            | 0.087   |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
| No. of TM attacks                                             | 1 \[0--2\]           | 2 \[1--3\]            | 0.011   |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
| No. of Brain attacks                                          | 1 \[0--2\]           | 0 \[0--1\]            | 0.021   |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
| Recent relapse, \<60 d                                        | 8 (6.9)              | 12 (19.0)             | 0.014   |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
| Annual Relapse Rate                                           | 0.3 \[0.2--0.6\]     | 0.5 \[0.3--0.8\]      | 0.001   |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
| Monophasic, n (%)                                             | 30 (25.6)            | 13 (20.6)             | 0.452   |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
| Simultaneous attacks[\*](#acn351070-note-0002){ref-type="fn"} | 6 (5.1)              | 7 (11.1)              | 0.225   |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
| (any time)                                                    |                      |                       |         |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
| EDSS, median (quartiles)                                      | 2.0 \[1.0--4.0\]     | 3.5 \[2.0--5.0\]      | 0.007   |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
| Treatments                                                    |                      |                       |         |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
| Any immunomodulating agent                                    | 103 (88.0)           | 63 (100.0)            | 0.002   |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
| Prednisolone                                                  | 11 (9.4)             | 31 (49.2)             | \<0.001 |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
| Azathioprine                                                  | 0 (0.0)              | 32 (50.0)             | \<0.001 |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
| Mycophenolate mofetil                                         | 2 (1.7)              | 11 (17.5)             | \<0.001 |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
| Interferon‐β                                                  | 33 (28.2)            | 0 (0.0)               | \<0.001 |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
| Teriflunomide                                                 | 31 (26.5)            | 0 (0.0)               | \<0.001 |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
| Dimethyl fumarate                                             | 7 (6.0)              | 0 (0.0)               | 0.098   |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
| Glatiramer acetate                                            | 4 (3.4)              | 0 (0.0)               | 0.289   |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
| Fingolimod                                                    | 7 (6.0)              | 0 (0.0)               | 0.054   |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
| Alemtuzumab                                                   | 12 (10.3)            | 0 (0.0)               | 0.009   |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
| Rituximab                                                     | 0 (0.0)              | 16 (25.4)             | \<0.001 |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
| Simoa markers                                                 |                      |                       |         |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
| NfL (pg/mL)[^‡^](#acn351070-note-0004){ref-type="fn"}         | 10.2 \[8.2--15.1\]   | 14.6 \[10.2--22.7\]   | 0.001   | 0.356                                        |
|                                                               |                      |                       |         |                                              |
|                                                               | (n = 113)            | (n = 61)              |         |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+
| GFAP (pg/mL)[^‡^](#acn351070-note-0004){ref-type="fn"}        | 95.0 \[70.0--130.4\] | 126.8 \[97.3--225.1\] | \<0.001 | 0.014                                        |
|                                                               |                      |                       |         |                                              |
|                                                               | (n = 112)            | (n = 56)              |         |                                              |
+---------------------------------------------------------------+----------------------+-----------------------+---------+----------------------------------------------+

EDSS, Expanded Disability Severity Scale; GFAP, glial fibrillary acidic protein; MS, multiple sclerosis; NfL, neurofilament light chain; NMOSD, neuromyelitis optica spectrum disorders; ON, optic neuritis; TM, transverse myelitis.

Simultaneous attacks of optic neuritis and transverse myelitis.

*P* value after adjustment for age, EDSS score, days from the last attack to blood sampling, recent relapse \<60 days.

Statistical analyses with these variables were performed with log‐transformed values.

John Wiley & Sons, Ltd

Serum GFAP and NfL levels were significantly and positively correlated with each other in both diseases (Pearson r = 0.550, *P* \< 0.001 for MS; Pearson r = 0.346, *P* = 0.009 for NMOSD). Subsequently, we evaluated the correlations between serum marker levels and clinical variables within each disease group (Table [2](#acn351070-tbl-0002){ref-type="table"}). NfL levels showed significant positive correlations with age in NMOSD (Pearson r = 0.480, *P* \< 0.001) but not MS (Pearson r = 0.177, *P* = 0.060). Moreover, positive NfL‐age correlations in NMOSD patients were more significant than those in MS patients (MS vs. NMOSD, *P* = 0.034; Fig. [1A](#acn351070-fig-0001){ref-type="fig"}). Meanwhile, GFAP levels increased significantly with age in both diseases (Fig. [1B](#acn351070-fig-0001){ref-type="fig"}). In terms of disease severity, both NfL and GFAP levels revealed significant positive correlations with EDSS scores in both diseases (Fig. [1C and D](#acn351070-fig-0001){ref-type="fig"}).

###### 

Correlations between serum markers and clinical variables.

+------------------+----------------------------------------------------+-------+----------------------------------------------------+----+-------+
| Correlation      | MS                                                 | NMOSD | *P* [^†^](#acn351070-note-0010){ref-type="fn"}     |    |       |
+==================+====================================================+=======+====================================================+====+=======+
| Age              |                                                    |       |                                                    |    |       |
+------------------+----------------------------------------------------+-------+----------------------------------------------------+----+-------+
| log NfL          | 0.177                                              | 113   | 0.480[\*\*\*](#acn351070-note-0009){ref-type="fn"} | 61 | 0.034 |
|                  |                                                    |       |                                                    |    |       |
|                  | (*P* = 0.060)                                      |       | (*P* \< 0.001)                                     |    |       |
+------------------+----------------------------------------------------+-------+----------------------------------------------------+----+-------+
| log GFAP         | 0.280[\*\*](#acn351070-note-0008){ref-type="fn"}   | 112   | 0.380[\*\*](#acn351070-note-0008){ref-type="fn"}   | 56 | 0.502 |
|                  |                                                    |       |                                                    |    |       |
|                  | (*P* = 0.003)                                      |       | (*P* = 0.004)                                      |    |       |
+------------------+----------------------------------------------------+-------+----------------------------------------------------+----+-------+
| Disease duration |                                                    |       |                                                    |    |       |
+------------------+----------------------------------------------------+-------+----------------------------------------------------+----+-------+
| log NfL          | −0.074                                             | 113   | −0.049                                             | 61 | 0.877 |
|                  |                                                    |       |                                                    |    |       |
|                  | *P* = 0.436)                                       |       | (*P* = 0.708)                                      |    |       |
+------------------+----------------------------------------------------+-------+----------------------------------------------------+----+-------+
| log GFAP         | 0.076                                              | 112   | 0.190                                              | 56 | 0.488 |
|                  |                                                    |       |                                                    |    |       |
|                  | (*P* = 0.423)                                      |       | (*P* = 0.162)                                      |    |       |
+------------------+----------------------------------------------------+-------+----------------------------------------------------+----+-------+
| EDSS             |                                                    |       |                                                    |    |       |
+------------------+----------------------------------------------------+-------+----------------------------------------------------+----+-------+
| log NfL          | 0.382[\*\*\*](#acn351070-note-0009){ref-type="fn"} | 113   | 0.369[\*\*](#acn351070-note-0008){ref-type="fn"}   | 61 | 0.926 |
|                  |                                                    |       |                                                    |    |       |
|                  | (*P* \< 0.001)                                     |       | (*P* = 0.003)                                      |    |       |
+------------------+----------------------------------------------------+-------+----------------------------------------------------+----+-------+
| log GFAP         | 0.317[\*\*\*](#acn351070-note-0009){ref-type="fn"} | 112   | 0.396[\*\*](#acn351070-note-0008){ref-type="fn"}   | 56 | 0.589 |
|                  |                                                    |       |                                                    |    |       |
|                  | (*P* = 0.001)                                      |       | (*P* = 0.003)                                      |    |       |
+------------------+----------------------------------------------------+-------+----------------------------------------------------+----+-------+

EDSS, expanded disability severity scale; GFAP, glial fibrillary acidic protein; MS, multiple sclerosis; NfL, neurofilament light chain; NMOSD, neuromyelitis optica spectrum disorders.

Significant correlations with age or EDSS sore,

*P* \< 0.05,

*P* \< 0.01,

*P* \< 0.001;

*P* value for differences in correlation coefficients between the MS and NMOSD groups.

John Wiley & Sons, Ltd

![Associations between serum biomarkers and age and Expanded Disability Status Scale (EDSS) score. (A) Serum neurofilament light chain (NfL) levels and age (MS: β = 1.009, *P* = 0.060; NMOSD: β = 1.038, *P* \< 0.001), (B) serum glial fibrillary acid protein (GFAP) levels and age (MS: β = 1.012, p = 0.003; NMOSD: β = 1.020, *P* = 0.004), (C) serum NfL levels and EDSS (MS: β = 1.134, p = 0.003; NMOSD: β = 1.175, *P* = 0.003), (D) serum GFAP levels and EDSS (MS: β = 1.086, p = 0.001; NMOSD: β = 1.125, *P* = 0.003). MS, multiple sclerosis; NMOSD, neuromyelitis optica spectrum disorders.](ACN3-7-992-g001){#acn351070-fig-0001}

We then analyzed the correlations between the serum markers and EDSS scores according to the age groups. First, patients were classified according to the decade of age (Table [3](#acn351070-tbl-0003){ref-type="table"}). However, the number of patients in each age group was small; particularly that in the youngest NMOSD patients (≤30 years) was too small (n = 2) to determine the correlation coefficient. Although no significant interactions were identified across the age groups, GFAP levels in NMOSD patients showed significant positive correlations with EDSS scores in the younger age groups (31--40 and 41--50 years), while NfL levels showed significant positive correlations with EDSS scores in the older age groups (51--60 and ≥61 years).

###### 

Correlations between serum markers and Expanded Disability Status Scale scores according to age (by decade).

             MS                                                 NMOSD   *P* [^†^](#acn351070-note-0016){ref-type="fn"} (MS vs. NMOSD)                                                                                             
  ---------- -------------------------------------------------- ------- --------------------------------------------------------------- --------- ------------------------------------------------ ---- ------- --------- ------- ---------
  Log NfL                                                                                                                                                                                                                         
  ≤30        −0.004                                             18                                                                                NA                                               2    NA      NA        NA      NA
  31−40      0.526[\*\*](#acn351070-note-0014){ref-type="fn"}   29      0.070                                                           0.280     −0.124                                           7                      0.187   0.935
  41−50      0.327                                              32      0.280                                                           \>0.999   −0.330                                           18   0.698   \>0.999   0.032   0.160
  51−60      0.074                                              24      0.817                                                           \>0.999   0.568[\*](#acn351070-note-0013){ref-type="fn"}   19   0.169   0.676     0.086   0.430
  ≥61        0.226                                              10      0.609                                                           \>0.999   0.567[\*](#acn351070-note-0013){ref-type="fn"}   15   0.184   0.736     0.385   \>0.999
  Log GFAP                                                                                                                                                                                                                        
  ≤30        0.315                                              18                                                                                NA                                               2    NA      NA        NA      NA
  31−40      0.168                                              29      0.629                                                           \>0.999   0.740[\*](#acn351070-note-0013){ref-type="fn"}   7                      0.147   0.735
  41−50      0.055                                              31      0.397                                                           \>0.999   0.589[\*](#acn351070-note-0013){ref-type="fn"}   16   0.631   \>0.999   0.064   0.320
  51−60      0.421[\*](#acn351070-note-0013){ref-type="fn"}     24      0.716                                                           \>0.999   0.300                                            18   0.255   \>0.999   0.680   \>0.999
  ≥61        0.058                                              10      0.558                                                           \>0.999   0.118                                            13   0.160   0.640     0.902   \>0.999

EDSS, expanded disability severity scale; GFAP, glial fibrillary acidic protein; MS, multiple sclerosis; NA, not available; NfL, neurofilament light chain; NMOSD, neuromyelitis optica spectrum disorders.

Significant correlations with EDSS score,

*P* \< 0.05,

*P* \< 0.01,

*P* \< 0.001;

*P* value for differences in correlation coefficients between the MS and NMOSD groups;

*P* value for differences in correlation coefficients between the age groups within the disease group (vs. the reference, MS: ≤30 years, NMOSD: 31−40 years).

John Wiley & Sons, Ltd

To increase the number of patients evaluated in each group, we established three age groups (≤ 44, 45--54, and ≥55 years)[^22^](#acn351070-bib-0022){ref-type="ref"}, [^23^](#acn351070-bib-0023){ref-type="ref"}, [^24^](#acn351070-bib-0024){ref-type="ref"} (Table [4](#acn351070-tbl-0004){ref-type="table"}); 71 (39.4%), 54 (30.0%), and 55 (30.6%) patients were allocated to each age group, respectively. In MS patients, both NfL and GFAP levels tended to increase with EDSS scores in all age groups (Fig. [2A and B](#acn351070-fig-0002){ref-type="fig"}). The degrees of these correlations between serum markers and EDSS scores did not differ significantly among the age groups. However, in NMOSD patients, correlations between serum markers and EDSS scores were significantly different among the age groups (Fig. [2C and D](#acn351070-fig-0002){ref-type="fig"}). In particular, GFAP levels showed significantly stronger positive correlations with EDSS scores in the youngest, rather than the oldest, group (Pearson r, ≤ 44 years vs. ≥ 55 years, 0.754 vs. 0.075, p = 0.044 (corrected, Bonferroni)), whereas NfL levels exhibited opposite trends, with the strongest positive associations with EDSS scores seen in the oldest group (Pearson r, ≤44 years vs. ≥55 years, --0.182 vs. 0.594, p = 0.068 (corrected, Bonferroni)).

###### 

Correlations between serum markers and Expanded Disability Status Scale scores according to age.

  Three age groups   MS                                                 NMOSD   p[^†^](#acn351070-note-0023){ref-type="fn"} (MS vs. NMOSD)                                                                                               
  ------------------ -------------------------------------------------- ------- ------------------------------------------------------------ --------- -------------------------------------------------- ---- ------- --------- ------- ---------
  Log NfL                                                                                                                                                                                                                                
  ≤44                0.422[\*\*](#acn351070-note-0021){ref-type="fn"}   56                                                                             ‐0.182                                             13                     0.066   0.198
  45−54              0.301                                              32      0.546                                                        \>0.999   0.103                                              20   0.471   \>0.999   0.498   \>0.999
  ≥55                0.327                                              25      0.663                                                        \>0.999   0.594[\*\*](#acn351070-note-0021){ref-type="fn"}   28   0.034   0.068     0.590   \>0.999
  Log GFAP                                                                                                                                                                                                                               
  ≤44                0.196                                              56                                                                             0.754[\*\*](#acn351070-note-0021){ref-type="fn"}   12                     0.030   0.090
  45−54              0.396[\*](#acn351070-note-0020){ref-type="fn"}     31      0.346                                                        0.692     0.530[\*](#acn351070-note-0020){ref-type="fn"}     19   0.347   0.694     0.585   \>0.999
  ≥55                0.302                                              25      0.656                                                        \>0.999   0.075                                              25   0.022   0.044     0.433   \>0.999

EDSS, Expanded Disability Severity Scale; GFAP, glial fibrillary acidic protein; MS, multiple sclerosis; NfL, neurofilament light chain; NMOSD, neuromyelitis optica spectrum disorders.

Significant correlations with EDSS score,

*P* \< 0.05,

*P* \< 0.01,

*P* \< 0.001;

*P* value for differences in correlation coefficients between the MS and NMOSD groups;

*P* value for differences in correlation coefficients between the age groups within the disease group (vs. the reference \[the youngest\] group).

John Wiley & Sons, Ltd

![Associations between serum biomarkers and Expanded Disability Status Scale (EDSS) score according to three age groups. (A) Serum neurofilament light chain (NfL) levels and EDSS in MS patients (≤44 years: β = 1.191, *P* = 0.001; 45--54 years: β = 1.075, *P* = 0.094; ≥55 years: β = 1.085, *P* = 0.111), (B) serum glial fibrillary acid protein (GFAP) levels and EDSS in MS patients (≤44 years: β = 1.055, *P* = 0.149; 45--54 years: β = 1.118, *P* = 0.028; ≥ 55 years: β = 1.082, *P* = 0.142), (C) serum NfL levels and EDSS in NMOSD patients (≤44 years: β = 0.866, *P* = 0.553; 45--54 years: β = 1.031, *P* = 0.664; ≥55 years: β = 1.290, p = 0.001), (D) serum GFAP levels and EDSS in NMOSD patients (≤44 years: β = 1.222, *P* = 0.005; 45--54 years: β = 1.149, *P* = 0.020; ≥55 years: β = 1.025, *P* = 0.722). MS, multiple sclerosis; NMOSD, neuromyelitis optica spectrum disorders.](ACN3-7-992-g002){#acn351070-fig-0002}

In the analyses with the two age groups stratified by the median age, the findings were also similar (Supplementary Table [S1](#acn351070-sup-0001){ref-type="supplementary-material"} and Supplementary Figure [S1](#acn351070-sup-0001){ref-type="supplementary-material"}). Among MS patients, correlations between NfL (or GFAP) levels and EDSS scores were comparable between the age groups (Pearson r, \<47 years vs. ≥47 years, NfL: 0.403 vs. 0.275, p = 0.457; GFAP: 0.193 vs. 0.360, *P* = 0.355). Among NMOSD patients, correlations between GFAP levels and EDSS scores tended to be closer in younger, rather than older, patients (Pearson r, \<47 years vs. 47 years, 0.675 vs. 0.273, p = 0.041; Supplementary Figure [S1](#acn351070-sup-0001){ref-type="supplementary-material"}D); those between NfL levels and EDSS scores (Pearson r, 47 years vs. ≥47 years, --0.171 vs. 0.518, p = 0.016; Supplementary Figure [S1](#acn351070-sup-0001){ref-type="supplementary-material"}C) were also significantly different between the age groups.

Finally, because the period between the last attack and blood sampling was not comparable between patients with MS and NMOSD, we conducted age‐group analyses involving only patients who had experienced clinical attacks within the previous 5 years. In these patients, the interval between the last attack and blood sampling was similar between the diseases (MS \[n = 65\] vs. NMOSD \[n = 48\], median days \[interquartile range\], 475 \[101---835\] vs. 402 \[84---932\], *P* = 0.866). The age‐group analyses in these patients also showed results similar to those in all participants; the degree to which serum markers reflect disease severity tended to differ between the age groups in NMOSD, but not MS, patients (Table [5](#acn351070-tbl-0005){ref-type="table"} and Supplementary Table [S2](#acn351070-sup-0001){ref-type="supplementary-material"}).

###### 

Correlations between serum markers and Expanded Disability Status Scale scores according to age in only patients who had clinical attacks within the previous 5 years

  Three age groups   MS                                               NMOSD   *P* [^†^](#acn351070-note-0030){ref-type="fn"} (MS vs. NMOSD)                                                                                             
  ------------------ ------------------------------------------------ ------- --------------------------------------------------------------- --------- -------------------------------------------------- ---- ------- ------- ------- ---------
  Log NfL                                                                                                                                                                                                                               
  ≤44                0.386[\*](#acn351070-note-0027){ref-type="fn"}   42                                                                                −0.182                                             13                   0.095   0.285
  45−54              0.300                                            12      0.792                                                           \>0.999   0.182                                              16   0.382   0.764   0.772   \>0.999
  ≥55                0.495                                            11      0.727                                                           \>0.999   0.500[\*](#acn351070-note-0027){ref-type="fn"}     19   0.069   0.138   0.988   \>0.999
  Log GFAP                                                                                                                                                                                                                              
  ≤44                0.133                                            42                                                                                0.754[\*\*](#acn351070-note-0028){ref-type="fn"}   12                   0.022   0.066
  45−54              0.485                                            12      0.285                                                           0.570     0.567[\*](#acn351070-note-0027){ref-type="fn"}     15   0.442   0.884   0.797   \>0.999
  ≥55                0.379                                            11      0.495                                                           0.990     −0.113                                             16   0.012   0.024   0.254   0.762

EDSS, expanded disability severity scale; GFAP, glial fibrillary acidic protein; MS, multiple sclerosis; NfL, neurofilament light chain; NMOSD, neuromyelitis optica spectrum disorders.

Significant correlations with EDSS score,

*P* \< 0.05,

*P* \< 0.01,

*P* \< 0.001;

*P* value for differences in correlation coefficients between the MS and NMOSD groups;

*P* value for differences in correlation coefficients between the age groups within the disease group (vs. the reference \[the youngest\] group).

John Wiley & Sons, Ltd

Discussion {#acn351070-sec-0012}
==========

In this study, we found that serum GFAP levels increased with age in patients with either MS or NMOSD, while serum NfL levels showed significant positive correlations with age in NMOSD only. Although serum GFAP levels were significantly higher in NMOSD than in MS patients, both serum NfL and GFAP levels demonstrated significant positive correlations with EDSS scores in both diseases. Notably, the degrees of correlations between serum markers and disease severity in MS were similar across the age groups, but those in NMOSD were significantly different among the age groups.

NfL and GFAP are cytoskeletal scaffolding proteins in neurons and astrocytes, respectively, which are released into the extracellular space following neuroaxonal or glial injury.[^25^](#acn351070-bib-0025){ref-type="ref"}, [^26^](#acn351070-bib-0026){ref-type="ref"} Because these proteins can be measured from body fluids including CSF and blood, they have been suggested as a promising biomarker in CNS demyelinating diseases. Higher levels of NfL were reported to be associated with high disease activity (recent relapses) and severity (higher EDSS scores), and to predict poor prognosis (conversion to MS after optic neuritis or clinically isolated syndrome).[^27^](#acn351070-bib-0027){ref-type="ref"}, [^28^](#acn351070-bib-0028){ref-type="ref"} NfL was even suggested as a marker to reflect treatment responses, as immunomodulatory agents significantly decreased NfL levels along with inflammation during treatment.[^29^](#acn351070-bib-0029){ref-type="ref"}, [^30^](#acn351070-bib-0030){ref-type="ref"}, [^31^](#acn351070-bib-0031){ref-type="ref"} GFAP levels were also reported to be related with disease activity and severity in these patients.[^4^](#acn351070-bib-0004){ref-type="ref"}, [^7^](#acn351070-bib-0007){ref-type="ref"} In addition, a possibility has been raised that GFAP levels could discriminate anti‐AQP4 antibody‐seropositive NMOSD from other demyelinating diseases such as anti‐MOG antibody‐associated diseases.[^32^](#acn351070-bib-0032){ref-type="ref"}, [^33^](#acn351070-bib-0033){ref-type="ref"} However, although fluid levels of these proteins are prone to be affected by aging and neurodegeneration, this variability has received little attention. This is the first study to analyze the clinical value of serum levels of these proteins according to patient age in CNS demyelinating diseases.

Our results confirm the clinical value of these proteins as a biomarker, showing that serum levels of NfL and GFAP were both closely correlated with disease severity. Serum NfL levels may plausibly correlate with increasing EDSS scores, because both MS and NMOSD are accompanied by damage to neuronal axons.[^1^](#acn351070-bib-0001){ref-type="ref"}, [^34^](#acn351070-bib-0034){ref-type="ref"}, [^35^](#acn351070-bib-0035){ref-type="ref"} Meanwhile, the relationship between GFAP levels and EDSS scores warrants discussion. Astroglial activation has been implicated in inflammatory demyelinating diseases in two aspects: (a) it may trigger immune‐system cascades, resulting in neurodegeneration, or (b) it may be involved in terminating immune responses, thus promoting remyelination.[^26^](#acn351070-bib-0026){ref-type="ref"} However, the close relationship between MS disease activity and GFAP levels in the CSF has been controversial.[^35^](#acn351070-bib-0035){ref-type="ref"}, [^36^](#acn351070-bib-0036){ref-type="ref"}, [^37^](#acn351070-bib-0037){ref-type="ref"} These uncertain results may have been due to the diagnostic insensitivity of CSF GFAP assays. Serum GFAP levels may be more sensitive than CSF GFAP levels in reflecting astroglial damage[^4^](#acn351070-bib-0004){ref-type="ref"} because GFAP expression occurs mainly in astrocyte branches, which constitute the blood--brain barrier. GFAP might preferentially drain into the blood rather than into the CSF.[^4^](#acn351070-bib-0004){ref-type="ref"}

Both serum NfL and GFAP levels were also likely to increase with age. These positive associations may reflect the presence of age‐related neurodegeneration.[^11^](#acn351070-bib-0011){ref-type="ref"}, [^13^](#acn351070-bib-0013){ref-type="ref"}, [^14^](#acn351070-bib-0014){ref-type="ref"} However, the positive NfL‐age correlations in MS patients were not statistically significant and were substantially weaker than those in NMOSD patients. Although positive correlations between NfL levels and age in MS have been suggested,[^6^](#acn351070-bib-0006){ref-type="ref"}, [^8^](#acn351070-bib-0008){ref-type="ref"} the association was denied in a recent meta‐analysis that evaluated 10,059 individuals with neurological disorders.[^38^](#acn351070-bib-0038){ref-type="ref"} In the cited meta‐analysis, while healthy controls revealed significant positive correlations between age and NfL levels, patients with progressive diseases including fronto‐temporal dementia, amyotrophic lateral sclerosis, parkinsonian syndromes, and MS did not.[^38^](#acn351070-bib-0038){ref-type="ref"} These data suggest that neuropathological processes in progressive diseases may cause a plateau in NfL levels or mask age associations.[^38^](#acn351070-bib-0038){ref-type="ref"} Conversely, NMOSD, which lacks progressive phase,[^1^](#acn351070-bib-0001){ref-type="ref"} may have accentuated the positive relationship of NfL levels with age.

The clinical implications of the serum markers were different between MS and NMOSD, depending on patient age. In MS patients, the degrees of correlation between NfL (or GFAP) levels and disease severity were similar among age groups, suggesting that neuronal and astrocytic damage may occur at similar degrees throughout patients' lifetime. These findings may reflect the steady and progressive disease processes, independent of relapsing events, in MS.[^1^](#acn351070-bib-0001){ref-type="ref"} On the contrary, in NMOSD patients, serum GFAP levels in the younger group showed stronger positive associations with disease severity than those in the older group. The high serum GFAP levels detected in patients with NMOSD may arise from immune‐mediated cellular cytotoxicity targeting the AQP4 water channel, which is densely expressed in astrocytes.[^39^](#acn351070-bib-0039){ref-type="ref"}, [^40^](#acn351070-bib-0040){ref-type="ref"}, [^41^](#acn351070-bib-0041){ref-type="ref"} These pathogenic processes may result in close correlations between GFAP levels and disease severity.[^36^](#acn351070-bib-0036){ref-type="ref"} With aging, however, the associations between GFAP levels and disease severity may become complicated and less specific. Along with neurodegeneration (i.e., increasing neuronal damage), secondary changes such as mixed changes in cortical GFAP‐positive astrocytes (decreases seen in layer I but increases seen in layers II--IV) and increased astrogliosis (i.e., increased extent of GFAP in the brain) in chronic lesions develop in patients with NMOSD;[^26^](#acn351070-bib-0026){ref-type="ref"}, [^35^](#acn351070-bib-0035){ref-type="ref"} these changes may weaken the degrees of correlation between GFAP and EDSS scores. Conversely, correlations between NfL levels and EDSS scores were not significant in younger patients but were prominent in older patients with NMOSD. Taken together, although astrocytic damage may be characteristic of NMOSD, particularly in younger patients, other age‐related processes may also be involved and become important in older patients with NMOSD.

Could then serum GFAP levels be a specific biomarker for NMOSD? We regard that the answer may also depend on patient age. In younger patients without age‐related neurodegeneration, serum GFAP levels may be a specific biomarker for NMOSD rather than for MS, while in older patients with advanced neurodegeneration, the specificity of GFAP as a diagnostic marker may be compromised. In old patients, serum levels of GFAP, which can increase with neurodegeneration and secondary changes, may reflect neurological disability in MS as well as NMOSD. Because the number of participants is small in this study, further larger studies to confirm this possibility are necessary.

The study limitations include the recruitment of individuals belonging to a single ethnicity (Korean) from a single center, which decreases the results' general applicability. Additionally, because the number of patients in this study was relatively small, the degrees of correlations were not fully stratified according to the decade of age, leading to definition of the arbitrary age groups. We attempted to overcome this limitation by using two additional different age stratification criteria, and acquired consistent findings. MS and NMOSD patients had different clinical statuses at the time of blood sampling. These differences may have affected serum levels of Simoa markers and their clinical values. However, the results were reproduced even when we evaluated only the patients who had endured an attack within the previous 5 years to balance the intervals between the diseases. In addition, although we have adopted a dilution concentration according to the guideline and previous works,[^6^](#acn351070-bib-0006){ref-type="ref"}, [^7^](#acn351070-bib-0007){ref-type="ref"}, [^8^](#acn351070-bib-0008){ref-type="ref"}, [^9^](#acn351070-bib-0009){ref-type="ref"}, [^21^](#acn351070-bib-0021){ref-type="ref"} a possibility of a "hook effect,"[^42^](#acn351070-bib-0042){ref-type="ref"} diverging from the linear range of the standard curve, should be considered, because we used multi‐fold sample dilution in serum analyses. Therefore, the results should be interpreted with caution especially for high concentration values. Finally, the clinical implications of biomarkers were evaluated only in terms of correlations between serum levels and disease severity. Follow‐up data collected longitudinally to evaluate the clinical value of these biomarkers (e.g., predicting relapses and/or progressions) according to patient age are warranted.

In conclusion, although serum NfL and GFAP levels may reflect disease severity in both MS and NMOSD, the degrees to which these markers reflect disease severity differ significantly with patient age in NMOSD, but not in MS. These findings may indicate different pathogenic processes between MS and NMOSD, and suggest the need for different strategies to interpret biomarker data according to patient age and disease type.
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**Table S1** **.** Correlations between serum markers and Expanded Disability Status Scale (EDSS) scores according to two age groups, separated by the median age (47 years).

**Table S2** **.** Correlations between serum markers and Expanded Disability Status Scale (EDSS) scores according to two age groups, containing only patients who had experienced clinical attacks within the previous 5 years.

**Figure S1** **.** Associations between serum biomarkers and Expanded Disability Status Scale (EDSS) scores according to two age groups.
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